Silk Road Medical Competitors, Revenue, Alternatives and Pricing
Overview

Industry Ranking
Estimated Revenue & Financials
- Silk Road Medical's estimated annual revenue is currently $47.7M per year.
- Silk Road Medical received $47.0M in venture funding in July 2017.
- Silk Road Medical's estimated revenue per employee is $251,000
- Silk Road Medical's total funding is $146.7M.
Employee Data
- Silk Road Medical has 190 Employees.
- Silk Road Medical grew their employee count by 31% last year.
- Silk Road Medical currently has 1 job openings.
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Online Review | Pricing |
---|---|---|---|---|---|---|
$30.4M | 121 | 11% | N/A | - | N/A | |
$12M | 48 | 45% | N/A | - | N/A | |
$18.8M | 75 | N/A | N/A | - | N/A | |
$26.9M | 107 | 3% | N/A | 5/5 | N/A | |
$20.8M | 83 | 28% | N/A | - | N/A | |
$25.4M | 101 | -6% | N/A | - | N/A | |
N/A | 4910 | N/A | N/A | - | N/A | |
$5.8M | 23 | N/A | N/A | - | N/A | |
$19.8M | 79 | N/A | N/A | - | N/A | |
$495M | 1972 | N/A | N/A | - | N/A |
What Is Silk Road Medical?
Silk Road Medical, Inc. is a privately held company located in Sunnyvale, California, dedicated to preventing the devastating burden of stroke through surgical innovation. The company develops and manufactures less-invasive medical devices to improve the treatment of vascular disease through proprietary transcarotid therapies. By innovating around proven surgical principles and developing breakthrough technology for vascular specialists, we can improve the lives of people with carotid artery disease. Our history is one of deep collaboration with vascular specialists and our future will be guided by continuous learning, observation and improvement. For more information on the company, visit our website at http://silkroadmed.com/. The TransCarotid Artery Revascularization (TCAR) Procedure is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The ENROUTE® Transcarotid Neuroprotection and Stent System are the first and only products specifically designed and indicated for TCAR in high surgical risk patients that need carotid intervention. For more information about the TCAR procedure and essential prescribing information, please visit http://silkroadmed.com/ifus/. For more information about carotid artery disease and the risks involved with any intervention (e.g. bleeding, death, myocardial infarction, restenosis, stroke, TIA, vessel dissection, vessel occlusion, etc.), please visit http://silkroadmed.com/disease-and-treatment-options/.
keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals190
Number of Employees
$47.7M
Revenue (est)
1
Current Jobs
31%
Employee Growth %
$146.7M
Total Funding
N/A
Valuation
N/A
Accelerator
B2C
Type
Silk Road Medical News
Based in Sunnyvale, California, Silk Road Medical (SILK) is a medical device company focused on reducing the risk of stroke and its ...
Silk Road Medical Announces Closing of Follow-on Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares.
The biggest gainers of the session on the Wall Street include Silk Road Medical, Inc (NASDAQ:SILK), which rose 1.53 points or 4.44% to trade ...
Silk Road Medical Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2014-08-15 | $15.0M | Undisclosed | Article | |
2015-10-21 | $57.0M | Undisclosed | CRG | Article |
2017-07-19 | $47.0M | Undisclosed | Janus Capital | Article |
Silk Road Medical Executive Hires
Date | Name | Title | Reference |
---|---|---|---|
2014-07-24 | Michael P. Wallace | CTO | Article |
2017-10-12 | Tammy Leitsinger | vp Medial Affairs/Professional Education | Article |